| Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. | |
| | |
MedLine Citation:
|
PMID: 20210253 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Among angiosarcomas, radiation-induced breast sarcomas (RIBS) represent a well-known entity generally characterized by a poor outcome, especially in patients with advanced disease. Despite the unfavorable prognosis, some chemotherapeutic agents have been used to treat these malignancies, occasionally with success. Treatments with demonstrated activity against sarcomas include ifosfamide-based regimens and, more recently, taxane derivatives. We report a case of a patient having a secondary breast angiosarcoma recurring early after surgery, who achieved complete remission following treatment with weekly paclitaxel. After 4 years of maintenance therapy, with an interval between consecutive administrations of no longer than 3 weeks, the patient is still in complete remission. A locoregional recurrence was documented twice during this period, the first as a consequence of a brief treatment interruption and the second because of a treatment delay. Nonetheless, in both instances a new complete remission was rapidly achieved with the resumption of the same treatment, without evidence of any significant adverse effects. We discuss the highly unusual behavior of this malignancy and the possible role of the two different mechanisms of action of paclitaxel-antiangiogenic versus cytotoxic-depending on the schedule of administration, with evidence of "false" drug-resistance. |
| | |
Authors:
|
Donatella Gambini; Roberto Visintin; Elisa Locatelli; Barbara Galassi; Claudia Bareggi; Letterio Runza; Francesco Onida; Maurizio Tomirotti |
Related Documents
:
|
7481853 - Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. 12399133 - A phase ii study of non-platinum based chemotherapy with paclitaxel and vinorelbine in ... 16972243 - A phase ii trial of thalidomide and cyclophosphamide in patients with recurrent or refr... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Tumori Volume: 95 ISSN: 0300-8916 ISO Abbreviation: Tumori Publication Date: 2009 Nov-Dec |
Date Detail:
|
Created Date: 2010-03-08 Completed Date: 2010-03-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0111356 Medline TA: Tumori Country: Italy |
Other Details:
|
Languages: eng Pagination: 828-31 Citation Subset: IM |
Affiliation:
|
Medical Oncology Unit, IRCCS Foundation "Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena", Milan, Italy. gambini.donatella@policlinico.mi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Angiogenesis Inhibitors / administration & dosage, therapeutic use* Antineoplastic Agents, Phytogenic / administration & dosage, therapeutic use* Breast Neoplasms / drug therapy*, secondary, surgery Drug Administration Schedule Female Hemangiosarcoma / drug therapy*, secondary, surgery Humans Mastectomy, Segmental* Neoplasm Recurrence, Local / drug therapy* Neoplasms, Second Primary / drug therapy Paclitaxel / administration & dosage, therapeutic use* Remission Induction Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents, Phytogenic; 33069-62-4/Paclitaxel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Challenging diagnosis of ileal gastrointestinal stromal tumor presenting with obscure digestive blee...
Next Document: Helical tomotherapy for scalp recurrence of primary eccrine mucinous adenocarcinoma.